These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 16928345)

  • 1. Current treatment of mild cognitive impairment and Alzheimer's disease.
    Knopman DS
    Curr Neurol Neurosci Rep; 2006 Sep; 6(5):365-71. PubMed ID: 16928345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The expert consensus guideline series. Treatment of dementia and its behavioral disturbances. Introduction: methods, commentary, and summary.
    Alexopoulos GS; Jeste DV; Chung H; Carpenter D; Ross R; Docherty JP
    Postgrad Med; 2005 Jan; Spec No():6-22. PubMed ID: 17203561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Galantamine for vascular cognitive impairment.
    Birks J; Craig D
    Cochrane Database Syst Rev; 2006 Jan; (4):CD004746. PubMed ID: 23862185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's disease: early diagnosis and treatment.
    Chu LW
    Hong Kong Med J; 2012 Jun; 18(3):228-37. PubMed ID: 22665688
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mild cognitive impairment: to treat or not to treat.
    Kirshner HS
    Curr Neurol Neurosci Rep; 2005 Nov; 5(6):455-7. PubMed ID: 16263056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donepezil for mild and moderate Alzheimer's disease.
    Birks J S; Melzer D
    Cochrane Database Syst Rev; 2000; (2):CD001190. PubMed ID: 10796620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vitamin E and donepezil for the treatment of mild cognitive impairment.
    Petersen RC; Thomas RG; Grundman M; Bennett D; Doody R; Ferris S; Galasko D; Jin S; Kaye J; Levey A; Pfeiffer E; Sano M; van Dyck CH; Thal LJ;
    N Engl J Med; 2005 Jun; 352(23):2379-88. PubMed ID: 15829527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
    Ruthirakuhan M; Herrmann N; Suridjan I; Abraham EH; Farber I; Lanctôt KL
    Expert Opin Pharmacother; 2016 Dec; 17(18):2417-2429. PubMed ID: 27825018
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cognitive symptoms of Alzheimer's disease: clinical management and prevention.
    Joe E; Ringman JM
    BMJ; 2019 Dec; 367():l6217. PubMed ID: 31810978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
    Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
    J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and adverse effects of cholinesterase inhibitors and memantine in vascular dementia: a meta-analysis of randomised controlled trials.
    Kavirajan H; Schneider LS
    Lancet Neurol; 2007 Sep; 6(9):782-92. PubMed ID: 17689146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of ninjin'yoeito, a Kampo (traditional Japanese) medicine, on cognitive impairment and depression in patients with Alzheimer's disease: 2 years of observation.
    Kudoh C; Arita R; Honda M; Kishi T; Komatsu Y; Asou H; Mimura M
    Psychogeriatrics; 2016 Mar; 16(2):85-92. PubMed ID: 25918972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Use of Cholinesterase Inhibitors Across All Stages of Alzheimer's Disease.
    Deardorff WJ; Feen E; Grossberg GT
    Drugs Aging; 2015 Jul; 32(7):537-47. PubMed ID: 26033268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NIH state-of-the-science conference statement: Preventing Alzheimer's disease and cognitive decline.
    Daviglus ML; Bell CC; Berrettini W; Bowen PE; Connolly ES; Cox NJ; Dunbar-Jacob JM; Granieri EC; Hunt G; McGarry K; Patel D; Potosky AL; Sanders-Bush E; Silberberg D; Trevisan M
    NIH Consens State Sci Statements; 2010 Apr; 27(4):1-30. PubMed ID: 20445638
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New and emerging treatments for Alzheimer's disease.
    Corbett A; Smith J; Ballard C
    Expert Rev Neurother; 2012 May; 12(5):535-43. PubMed ID: 22550982
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Alzheimer's disease: current status and new perspectives.
    Scarpini E; Scheltens P; Feldman H
    Lancet Neurol; 2003 Sep; 2(9):539-47. PubMed ID: 12941576
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Donepezil for mild and moderate Alzheimer's disease.
    Birks JS; Melzer D; Beppu H
    Cochrane Database Syst Rev; 2000; (4):CD001190. PubMed ID: 11034704
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.